QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Enzyme Replacement Therapies—Classification and Pharmacovigilance

Test your understanding of the concepts covered by Enzyme Replacement Therapies: Classification and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A manufacturing process is changed to increase production capacity, but no clinical safety observation has emerged. Which statement is most appropriate?

The change automatically constitutes a pharmacovigilance signal The change is assessed through quality and regulatory comparability processes; pharmacovigilance remains relevant if safety evidence or a clinical hypothesis emerges The change can be ignored because manufacturing cannot affect biological products A new risk must be declared solely because the product is recombinant

Question 2 of 10 Which statement best describes the pharmacovigilance significance of anti-drug antibodies?

Their presence always proves clinically meaningful immunogenicity They are irrelevant unless a hypersensitivity reaction occurs They should be interpreted together with titre, timing, persistence and clinical, pharmacokinetic or pharmacodynamic findings They automatically establish loss of efficacy

Question 3 of 10 A patient with a progressive lysosomal storage disorder deteriorates clinically after several years of ERT. Which initial assessment is most appropriate?

Attribute the deterioration to treatment failure because it occurred during therapy Assume natural disease progression and close the case without further review Assess disease history, treatment exposure, interruptions, dose, biomarkers, immune findings and alternative explanations Treat the deterioration as proof of a manufacturing defect

Question 4 of 10 What is the appropriate relationship between pharmacovigilance and quality functions when a safety observation may involve a product-quality issue?

Pharmacovigilance should conduct all manufacturing investigations independently Quality should make the clinical safety conclusion without pharmacovigilance input Each function retains its responsibilities while exchanging relevant information through defined interfaces The issue should be excluded from pharmacovigilance until quality confirms a defect

Question 5 of 10 Why should therapeutic enzymes not automatically be treated as a single pharmacovigilance class?

Only non-recombinant enzymes can cause adverse reactions Products may differ in structure, manufacturing process, cellular uptake, indication and patient population All therapeutic enzymes have identical immunogenicity patterns Class effects are prohibited under EU pharmacovigilance principles

Question 6 of 10 Why is plasma concentration alone often insufficient to characterise exposure to an ERT product?

Protein medicines cannot be measured in plasma Clinical effect may depend on receptor-mediated uptake and delivery to a specific tissue or intracellular compartment Plasma concentration is unrelated to any pharmacological effect ERT products produce effects only through renal elimination

Question 7 of 10 Which classification approach is most useful for developing a product-specific pharmacovigilance strategy for ERT?

Classifying products only by the disease name Considering complementary dimensions such as biological function, destination, molecular source, route and dosing pattern Grouping all recombinant enzymes under one common safety profile Classifying products solely according to their marketing authorisation date

Question 8 of 10 A patient develops fever, flushing and hypotension during an ERT infusion. Which conclusion is most scientifically appropriate at case intake?

The event is an observation of an administration-related reaction; its precise mechanism remains to be assessed The event is definitively an IgE-mediated allergy The event is necessarily caused by neutralising antibodies The event should be classified as disease progression because the symptoms are nonspecific

Question 9 of 10 Which characteristic most fundamentally distinguishes enzyme replacement therapy from treatment with a conventional small-molecule medicine?

The administered protein must reach the relevant biological compartment and retain functional activity ERT products are always administered intravenously ERT products cannot produce pharmacodynamic effects measurable in laboratory tests ERT products act only by suppressing immune responses

Question 10 of 10 Which risk-management approach is most consistent with the article’s framework?

Apply the same additional risk-minimisation measure to every ERT product Use measures proportionate to evidence, clinical significance and the feasibility of preventing or detecting the risk Treat every theoretical mechanism as an established risk requiring mandatory restrictions Avoid additional studies because routine pharmacovigilance is always sufficient

Knowledge Assessment: Enzyme Replacement Therapies—Classification and Pharmacovigilance

Cookie Settings